Top

Published in:

01-10-2018 | Review Paper

Conjunctival Melanoma - Epidemiological Trends and Features

Authors: Snježana Kaštelan, Antonela Gverović Antunica, Lidija Beketić Orešković, Jasminka Salopek Rabatić, Boris Kasun, Ivana Bakija

Published in: Pathology & Oncology Research | Issue 4/2018

Abstract

Conjunctival melanoma is a rare but sight and life threatening malignancy. It accounts for 2%–5% of all ocular tumours and 5%–7% of all ocular melanomas with an incidence of 0.2–0.8 per million in the Caucasian population with rare cases reported in the non-Caucasians. In recent decades the incidence of uveal melanoma has been relatively stable whilst conjunctival and cutaneous melanoma have shown increasing incidence which may be connected to the result of environmental exposure to ultraviolet light. The dissimilarity in incidence between light and dark pigmented individuals observed in conjunctival melanomas compared to uveal and cutaneous melanomas may be related to differences in their histological structures and genetic profile. Recent molecular biological studies support the fact that each type of melanoma undergoes its own molecular changes and has characteristic biological behaviour. Further studies are required for each type of melanoma in order to ascertain their individual etiology and pathogenesis and based on this knowledge develop relevant preventative and treatment procedures.

Kao A, Afshar A, Bloomer M, Damato B (2016) Management of primary acquired melanosis, nevus, and conjunctival melanoma. Cancer Control 23(2):117–125 PMID: 27218788CrossRefPubMed

Vora GK, Demirci H, Marr B, Mruthyunjaya P (2017) Advances in the management of conjunctival melanoma. Surv Ophthalmol 62(1):26–42. Jun 16. pii: S0039–6257(16)30058–3. https://doi.org/10.1016/j.survophthal.2016.06.001. PMID:27321895

Wong JR, Nanji AA, Galor A, Karp CL (2014) Management of conjunctival malignant melanoma: a review and update. Expert Rev Ophthalmol 9(3):185–204. https://doi.org/10.1586/17469899.2014.921119 CrossRefPubMedPubMedCentral

Lim LA, Madigan MC, Conway RM (2013) Conjunctival melanoma: a review of conceptual and treatment advances. Clin Ophthalmol 6:521–531. https://doi.org/10.2147/OPTH.S38415 CrossRefPubMed

Norregaard JC, Gerner N, Jensen OA, Prause JU (1996) Malignant melanoma of the conjunctiva: occurrence and survival following surgery and radiotherapy in a Danish population. Graefes Arch Clin Exp Ophthalmol 234(9):569–572CrossRefPubMed

Lommatzsch PK, Lommatzsch RE, Kirsch I, Fuhrmann P (1990) Therapeutic outcome of patients suffering from malignant melanomas of the conjunctiva. Br J Ophthalmol 74(10):615–619CrossRefPubMedPubMedCentral

Seregard S, Kock E (1992) Conjunctival malignant melanoma in Sweden 1969-91. Acta Ophthalmol 70(3):289–296CrossRef

Isager P, Engholm G, Overgaard J, Storm H (2006) Uveal and conjunctival malignant melanoma in Denmark 1943–1997: observed and relative survival of patients followed through 2002. Ophthalmic Epidemiol 13(2):85–96CrossRefPubMed

Vajdic CM, Kricker A, Giblin M, McKenzie J, Aitken J, Giles GG, Armstrong BK (2003) Incidence of ocular melanoma in Australia from 1990 to 1998. Int J Cancer 105(1):117–122CrossRefPubMed

10.

Triay E, Bergman L, Nilsson B, All-Ericsson C, Seregard S (2009) Time trends in the incidence of conjunctival melanoma in Sweden. Br J Ophthalmol 93(11):1524–1528. https://doi.org/10.1136/bjo.2009.157933 Epub 2009 Jul 23CrossRefPubMed

11.

Vasalaki M, Fabian ID, Reddy MA, Cohen VM, Sagoo MS (2017) Ocular oncology: advances in retinoblastoma, uveal melanoma and conjunctival melanoma. Br Med Bull1 121(1):107–119. https://doi.org/10.1093/bmb/ldw053 Review. PMID: 28069617CrossRef

12.

Yu GP, Hu DN, McCormic S, Finger PT (2003) Conjunctival melanoma: is it increasing in the United States? Am J Ophthalmol 135(6):800–806CrossRefPubMed

13.

Tuomaala S, Kivelä T (2003) Conjunctival melanoma: is it increasing in the United States? Am J Ophthalmol 136(6):1189–1190CrossRefPubMed

14.

Chang AE, Karnell LH, Menck HR (1998) The national cancer data base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American college of surgeons commission on cancer and the american cancer society. Cancer. 83(8):1664–1678

15.

Tuomaala S, Eskelin S, Tarkkanen A, Kivelä T (2002) Population-based assessment of clinical characteristic predicting outcome of conjunctival melanoma in whites. Invest Ophthalmol Vis Sci 43(11):3399–3408PubMed

16.

Inskip PD, Devesa SS, Fraumeni JF Jr (2003) Trends in the incidence of ocular melanoma in the United States, 1974-1998. Cancer Causes Control 14(3):251–257CrossRefPubMed

17.

Missotten GS, Keijser S, De Keizer RJ, De Wolff-Rouendaal D (2005) Conjunctival melanoma in the Netherlands: a nationwide study. Invest Ophthalmol Vis Sci 46(1):75–82CrossRefPubMed

18.

Isager P, Østerlind A, Engholm G, Heegaard S, Lindegaard J, Overgaard J, Storm HH (2005) Uveal and conjunctival malignant melanoma in Denmark, 1943-97: incidence and validation study. Ophthalmic Epidemiol 12(4):223–232. https://doi.org/10.1080/09286580591000836 CrossRefPubMed

19.

Hu DN, Yu G, McCormick SA, Finger PT (2008) Population-based incidence of conjunctival melanoma in various races and ethnic groups and comparison with other melanomas. Am J Ophthalmol 145(3):418–423. https://doi.org/10.1016/j.ajo.2007.10.022 Epub 2008 Jan 11CrossRefPubMed

20.

Park SJ, Oh CM, Kim BW, Woo SJ, Cho H, Park KH (2015) Nationwide incidence of ocular melanoma in South Korea by using the national cancer registry database (1999-2011). Invest Ophthalmol Vis Sci 56(8):4719–4724. https://doi.org/10.1167/iovs.15-16532 CrossRefPubMed

21.

Larsen AC (2016) Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile. Acta Ophthalmol 94 Thesis 1:1–27. https://doi.org/10.1111/aos.13100. PMID:27192168

22.

Brownstein S (2004) Malignant melanoma of the conjunctiva. Cancer Control 11(5):310–316CrossRefPubMed

23.

Zembowicz A, Mandal RV, Choopong P (2010) Melanocytic lesions of the conjunctiva. Arch Pathol Lab Med 134(12):1785–1792. https://doi.org/10.1043/2009-0522-RAR.1. PubMedCrossRef

24.

Taban M, Traboulsi EI (2007) Malignant melanoma of the conjunctiva in children: a review of the international literature 1965-2006. J Pediatr Ophthalmol Strabismus 44(5):277–282PubMed

25.

Shields CL, Shields JA, Gündüz K, Cater J, Mercado GV, Gross N, Lally B (2000) Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Arch Ophthalmol 118(11):1497–1507CrossRefPubMed

26.

Seregard S (1998) Conjunctival melanoma. Surv Ophthalmol 42(4):321–350CrossRefPubMed

27.

Kenawy N, Lake SL, Coupland SE, Damato BE (2013) Conjunctival melanoma and melanocytic intra-epithelial neoplasia. Eye (Lond) 27(2):142–152. https://doi.org/10.1038/eye.2012.254 Epub 2012 Dec 7CrossRef

28.

Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, Vlajkovic S, Cekic S, Stefanovic V (2013) Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol 15;6(7):1230–1244.

29.

Shields CL, Shields JA (2009) Ocular melanoma: relatively rare but requiring respect. Clin Dermatol 27(1):122–133. https://doi.org/10.1016/j.clindermatol.2008.09.010 CrossRefPubMed

30.

Jakobiec FA, Folberg R, Iwamoto T (1989) Clinicopathologic characteristics of premalignant and malignant melanocytic lesions of the conjunctiva. Ophthalmology 96(2):147–166CrossRefPubMed

31.

Ophthalmic Oncology Task Force AJCC-UICC (2009) Malignant melanoma of the conjunctiva. In: Edge SE, Byrd DR, Carducci MA, Compton CA (eds) AJCC cancer staging manual. 7th edn. NY: Springer, New York, pp 539–546

32.

Paridaens AD, Minassian DC, McCartney AC, Hungerford JL (1994) Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases. Br J Ophthalmol 78(4):252–259CrossRefPubMedPubMedCentral

33.

Tuomaala S, Toivonen P, Al-Jamal R, Kivelä T (2007) Prognostic significance of histopathology of primary conjunctival melanoma in Caucasians. Curr Eye Res 32(11):939–952CrossRefPubMed

34.

Grossniklaus HE, Margo CE, Solomon AR (1999) Indeterminate melanocytic proliferations of the conjunctiva. Arch Ophthalmol 117:1131–1136CrossRefPubMed

35.

Henderson E, Margo CE (2008) Iris melanoma. Arch Pathol Lab Med 132(2):268–272PubMed

36.

Perez MT, Suster S (1999) Balloon cell change in cellular blue nevus. Am J Dermatopathol 21(2):181–184CrossRefPubMed

37.

Calonje E (2004) Non-melanocytic lesions mimicking melanocytic lesions. Pathology 36(5):387–395 PMID:15370107CrossRefPubMed

38.

Maly A, Epstein D, Meir K, Pe’er J (2008) Histological criteria for grading of atypia in melanocytic conjunctival lesions. Pathology 40(7):676–681CrossRefPubMed

39.

Shields CL, Kaliki S, Al-Dahmash SA, Lally SE, Shields JA (2012) American joint committee on cancer (AJCC) clinical classification predicts conjunctival melanoma outcomes. Ophthal Plast Reconstr Surg 28(5):313–323. https://doi.org/10.1097/IOP.0b013e3182611670 CrossRefPubMed

40.

Kivelä T, Kujala E (2013) Prognostication in eye cancer: the latest tumor, node, metastasis classification and beyond. Eye (Lond) 27(2):243–252. https://doi.org/10.1038/eye.2012.256 Review. PMID: 23258307CrossRef

41.

Yousef YA, Finger PT (2012) Predictive value of the seventh edition American joint committee on cancer staging system for conjunctival melanoma. Arch Ophthalmol 130(5):599–606. https://doi.org/10.1001/archophthalmol.2011.2566. CrossRefPubMed

42.

Esmaeli B, Eicher S, Popp J, Delpassand E, Prieto VG, Gershenwald JE (2001) Sentinel lymph node biopsy for conjunctival melanoma. Ophthal Plast Reconstr Surg 17(6):436–442CrossRefPubMed

43.

Sheng X, Li S, Chi Z, Si L, Cui C, Mao L, Lian B, Tang B, Wang X, Yan X, Kong Y, Dai J, Guo J (2015) Prognostic factors for conjunctival melanoma: a study in ethnic Chinese patients. Br J Ophthalmol 99(7):990–996. https://doi.org/10.1136/bjophthalmol-2014-305730 Epub 2015 Jan 16CrossRefPubMed

44.

Salcedo-Hernández RA, Luna-Ortiz K, Lino-Silva LS, Herrera-Gómez A, Villavicencio-Valencia V, Tejeda-Rojas M, Carrillo JF (2014) Conjunctival melanoma: survival analysis in twenty-two Mexican patients. Arq Bras Oftalmol 77(3):155–158CrossRefPubMed

45.

Larsen AC, Dahmcke CM, Dahl C, Siersma VD, Toft PB, Coupland SE, Prause JU, Guldberg P, Heegaard S (2015) A retrospective review of conjunctival melanoma presentation, treatment, and outcome and an investigation of features associated with BRAF mutations. JAMA Ophthalmol 133(11):1295–1303. https://doi.org/10.1001/jamaophthalmol.2015.3200 CrossRefPubMed

46.

Griewank KG, Westekemper H, Murali R, Mach M, Schilling B, Wiesner T, Schimming T, Livingstone E, Sucker A, Grabellus F, Metz C, Süsskind D, Hillen U, Speicher MR, Woodman SE, Steuhl KP, Schadendorf D (2013) Conjunctival Melanomas Harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin. Cancer Res 19(12):3143–3152. https://doi.org/10.1158/1078-0432.CCR-13-2368. CrossRef

47.

Lake SL, Jmor F, Dopierala J, Taktak AF, Coupland SE, Damato BE (2011) Multiplex ligation-dependent probe amplification of conjunctival melanoma reveals common BRAF V600E gene mutation and gene copy number changes. Invest Ophthalmol Vis Sci 52(8):5598–5604CrossRefPubMed

48.

Spendlove HE, Damato BE, Humphreys J, Barker KT, Hiscott PS, Houlston RS (2004) BRAF mutations are detectable in conjunctival but not uveal melanomas. Melanoma Res 14(6):449–452CrossRefPubMed

49.

Wallander ML, Layfield LJ, Emerson LL, Mamalis N, Davis D, Tripp SR, Holden JA (2011) KIT mutations in ocular melanoma: frequency and anatomic distribution. Mod Pathol 24(8):1031–1035. https://doi.org/10.1038/modpathol.2011.57 Epub 2011 Apr 8CrossRefPubMed

50.

51.

Patel M, Smyth E, Chapman PB, Wolchok JD, Schwartz GK, Abramson DH, Carvajal RD (2011) Therapeutic implications of the emerging molecular biology of uveal melanoma. Clin Cancer Res 17:2087–2100. https://doi.org/10.1016/j.jaad.2013.12.019 CrossRefPubMed

52.

Dogrusöz M, Jager MJ (2017) Genetic prognostication in uveal melanoma. Acta Ophthalmol (Nov 4). https://doi.org/10.1111/aos.13580

53.

Swaminathan SS, Field MG, Sant D, Wang G, Galor A, Dubovy SR, Harbour JW, Karp CL (2017) Molecular characteristics of conjunctival melanoma using whole-exome sequencing. 135(12):1434–1437. https://doi.org/10.1001/jamaophthalmol.2017.4837.

54.

Pandiani C, Béranger GE, Leclerc J, Ballotti R, Bertolotto C (2017) Focus on cutaneous and uveal melanoma specificities. Genes Dev 31(8):724–743. https://doi.org/10.1101/gad.296962.117 CrossRefPubMedPubMedCentral

55.

Kaštelan S, Gverović Antunica A, Beketić-Orešković L, Bakija I, Bogadi M (2017) Uveal melanoma: clinical features and diagnostic procedures. Libri Oncol 45(2-3):81-88

56.

Juzeniene A, Micu E, Porojnicu AC, Moan J (2012) Malignant melanomas on head/neck and foot: differences in time and latitudinal trends in Norway. J Eur Acad Dermatol Venereol 26(7):821–827. https://doi.org/10.1111/j.1468-3083.2011.04162.x Epub 2011 Jun 28CrossRefPubMed

57.

Yu GP, Hu DN, McCormick SA (2006) Latitude and incidence of ocular melanoma. Photochem Photobiol 82(6):1621–1626CrossRefPubMed

58.

Griewank KG, Murali R, Schilling B, Scholz S, Sucker A, Song M, Süsskind D, Grabellus F, Zimmer L, Hillen U, Steuhl KP, Schadendorf D, Westekemper H, Zeschnigk M (2013) TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer 23;109(2):497–501. https://doi.org/10.1038/bjc.2013.312.

59.

Rivolta C, Royer-Bertrand B, Rimoldi D, Schalenbourg A, Zografos L, Leyvraz S, Moulin A (2016) UV light signature in conjunctival melanoma; not only skin should be protected from solar radiation. J Hum Genet 61(4):361–362. https://doi.org/10.1038/jhg.2015.152 Epub 2015 Dec 10CrossRefPubMed

60.

Franco-Lie I, Iversen T, Robsahm TE, Abdelnoor M (2011) Incidence trends of melanoma of the skin compared with other localisations, in the Norwegian population, 1956-2005. Ann Oncol 22(6):1443–1450. https://doi.org/10.1093/annonc/mdq598 Epub 2010 Dec 6CrossRefPubMed

Title: Conjunctival Melanoma - Epidemiological Trends and Features
Authors: Snježana Kaštelan
Antonela Gverović Antunica
Lidija Beketić Orešković
Jasminka Salopek Rabatić
Boris Kasun
Ivana Bakija
Publication date: 01-10-2018
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 4/2018
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-018-0419-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2018

The ER – Glycogen Particle – Phagophore Triangle: A Hub Connecting Glycogenolysis and Glycophagy?

The Histone Acetylation Modifications of Breast Cancer and their Therapeutic Implications

Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) – Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy

TIMP3 Promoter Methylation Represents an Epigenetic Marker of BRCA1ness Breast Cancer Tumours

Intratumoral Heterogeneity of Somatic Mutations for NRIP1, DOK1, ULK1, ULK2, DLGAP3, PARD3 and PRKCI in Colon Cancers

Aspects of Modern Biobank Activity – Comprehensive Review

Keynote webinar | Spotlight on antibody–drug conjugates in cancer